NCT02180698View on ClinicalTrials.gov

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 17, 2014

Primary Completion Date

October 7, 2016

Study Completion Date

October 7, 2016

Conditions
Stage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

RADIATION

Radiation Therapy

Undergo radiation therapy

DRUG

TLR4 Agonist GLA-SE

Given intratumorally

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT02180698 - TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter